Original Article
A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer
N Engl J Med 2000; 343:1217-1222October 26, 2000
- Abstract
Background
We conducted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is superior to thoracic radiotherapy alone in prolonging survival and preventing local recurrence in patients with completely resected stage II or IIIa non–small-cell lung cancer.
Methods
After surgical staging and resection of the tumor (usually by lobectomy or pneumonectomy), the patients were randomly assigned to receive either four 28-day cycles of cisplatin (60 mg per square meter of body-surface area intravenously on day 1) and etoposide (120 mg per square meter intravenously on days 1, 2, and 3) administered concurrently with radiotherapy (a total of 50.4 Gy, given in 28 daily fractions) or radiotherapy alone (a total of 50.4 Gy, given in 28 daily fractions).
Results
Of the 488 patients who were enrolled in the study, 242 were assigned to receive radiotherapy alone and 246 were assigned to receive chemotherapy and radiotherapy. The median duration of follow-up was 44 months. Treatment-associated mortality was 1.2 percent in the group given radiotherapy alone and 1.6 percent in the group given chemotherapy and radiotherapy. The median survival was 39 months in the group given radiotherapy and 38 months in the group given chemotherapy and radiotherapy (P= 0.56 by the log-rank test). The relative likelihood of survival among patients assigned to receive chemotherapy and radiotherapy, as compared with those assigned to receive radiotherapy alone, was 0.93 (95 percent confidence interval, 0.74 to 1.18). Intrathoracic disease recurred within the radiation field in 30 of 234 patients (13 percent) in the group given radiotherapy and in 28 of 236 patients (12 percent) in the group given chemotherapy and radiotherapy (P=0.84); data on recurrence were not available for 18 patients.
Conclusions
As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non–small-cell lung cancer.
Media in This Article
Figure 1
Kaplan–Meier Estimates of Overall Survival among Patients with Stage II or IIIa Non–Small-Cell Lung Cancer, According to Whether They Received Postoperative Radiotherapy Alone or Radiotherapy and Chemotherapy.Table 1
Characteristics of the Patients.Article Activity
- Article
The presence of metastatic tumor in the intrathoracic lymph nodes markedly worsens the prognosis of patients with resected non–small-cell lung cancer (which includes squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma). Despite the removal of all visible tumor, cancer recurs in most patients with metastases to intrapleural or extrapleural lymph nodes. The Lung Cancer Study Group investigated the value of postoperative therapy in such patients and found that radiotherapy, combination chemotherapy (with cyclophosphamide, doxorubicin, and cisplatin), or both improved local control and disease-free survival but not overall survival.1-3
Regimens containing higher doses of cisplatin4 or etoposide plus cisplatin also showed promise,5,6 but many physicians questioned the efficacy of any type of postoperative chemotherapy and considered irradiation to be standard therapy in patients with intrathoracic lymph-node metastases. To investigate the possible benefits of adjuvant chemotherapy after the resection of stage II and stage IIIa non–small-cell lung cancer, we conducted a randomized trial comparing radiotherapy alone with chemotherapy and radiotherapy.
Methods
Study Design
This trial was initiated by the Eastern Cooperative Oncology Group (ECOG) in April 1991, and enrollment was stopped in February 1997. The following groups also participated: the Radiation Therapy Oncology Group, the North Central Cancer Treatment Group, Cancer and Leukemia Group B, and the Southwest Oncology Group.
Randomization was performed over the telephone at a central site, and all patients underwent randomization within 42 days after surgery. The institutional review board or the ethics committee at each site reviewed and approved the protocol. Written informed consent was obtained from all patients or their surrogates.
The patients were stratified according to histologic findings (squamous-cell carcinoma vs. other types), extent of weight loss during the six months preceding enrollment (<5 percent of body weight vs. ≥5 percent of body weight), extent of nodal involvement according to the tumor–node–metastasis (TNM) staging system (N1 [metastasis to lymph nodes in the peribronchial region, ipsilateral hilar region, or both, including direct extension] vs. N2 [metastasis to ipsilateral mediastinal lymph nodes]), and the type of lymph-node dissection (systematic sampling vs. complete dissection).
Patients assigned to the control group (the group receiving radiotherapy alone) received a total of 50.4 Gy in 28 daily fractions of 1.8 Gy. The initial portion of the treatment was administered with anteroposterior and posteroanterior portals with a limit of 36 to 42 Gy. The remainder of the treatment involved the same target volume but used a lateral or oblique field arrangement that prevented any level of the spinal cord from receiving more than 45 Gy. An additional 10.8 Gy (six fractions of 1.8 Gy) was administered to nodal levels at which extracapsular extension of nodal metastases was documented. The combined-treatment group received the identical regimen of radiotherapy administered concomitantly with etoposide (120 mg per square meter of body-surface area intravenously on days 1, 2, and 3) and cisplatin (60 mg per square meter intravenously on day 1). Chemotherapy was initiated within 24 hours after radiotherapy was begun and repeated every 28 days for a total of four cycles.
Eligibility Criteria
Patients who had undergone complete resection of pathologically documented stage II (T1–2N1M0) or stage IIIa (T1–2N2M0 or T3N1–2M0) non–small-cell lung cancer were eligible for the study. Patients with multifocal bronchoalveolar tumors within the same lobe or different ipsilateral lobes were not eligible. We used a lung-cancer staging system that was current during the years 1986 to 1997.7 In this staging system, T1 indicates a primary tumor that is 3 cm or less in its greatest dimension, with no invasion of lobar bronchus or pleural involvement; T2 indicates a primary tumor that is larger than 3 cm or a primary tumor of any size that involves the visceral pleura or main bronchus or is associated with atelectasis or obstructive pneumonitis that extends to the hilar region; T3 indicates a primary tumor of any size that has invaded the chest wall, diaphragm, or mediastinal pleura or pericardium but does not involve the heart, great vessels, trachea, esophagus, or vertebral body or a tumor in the main bronchus that is within 2 cm of the carina but does not involve the carina; and M0 indicates the absence of distant metastasis. Lymph-node levels were defined according to the criteria of the American Thoracic Society.8 Peribronchial and hilar lymph nodes (levels 10 to 13 [hilar, interlobar, lobar, and segmental nodes, respectively]) were labeled N1, whereas ipsilateral mediastinal lymph nodes (levels 1 to 9 [highest mediastinal, upper paratracheal, pretracheal and retrotracheal, low-er paratracheal, subaortic, para-aortic, subcarinal, paraesophageal, and pulmonary-ligament nodes, respectively]) were labeled N2.
All patients underwent either systematic sampling of lymph nodes or complete dissection of mediastinal lymph nodes at levels 4, 7, and 10 during a right-sided thoracotomy and at level 7 and level 5 or 6 or both during a left-sided thoracotomy. During systematic sampling, a representative lymph node was removed at the specified levels. During complete dissection all lymph nodes at the specified levels were removed. All operative notes and pathology reports were reviewed by a single investigator to ensure that the labeling and the staging of lymph nodes were uniform. A videotape illustrating the technique of the dissection of mediastinal lymph nodes was made available to all participating institutions.9
Cervical mediastinoscopy was required beginning in June 1993 if the preoperative computed tomographic scan demonstrated mediastinal lymph nodes that exceeded 1.5 cm in the short-axis diameter. Patients with multilevel lymph-node metastases, extranodal disease, or contralateral mediastinal disease at mediastinoscopy were ineligible for the study. A lobectomy or pneumonectomy was required, though segmental or wedge resections were permitted during the first months of the study. Postoperatively, patients had to have a forced expiratory volume in one second that would allow them to tolerate the proposed radiotherapy, as well as an ECOG performance status of 0 or 1.
Statistical Analysis
Fisher's exact test was used to compare groups with respect to categorical end points (e.g., recurrence).10 A P value of less than 0.05 was considered to indicate statistical significance, and all resulting P values were two-tailed. Survival was calculated from the date of randomization to death. Data on patients who were alive were censored on the date on which they were last known to be alive. The time to recurrence was also computed from the date of randomization. Data on patients without recurrent disease were censored on the date on which they were last known to have stable disease. Data on patients who were alive and free of recurrent disease were censored at the time of the last follow-up visit.
Survival and time to recurrence were estimated with use of the Kaplan–Meier method,11 and differences between groups were compared with the log-rank test.12 A P value of less than 0.05 was considered to indicate statistical significance, and all resulting P values were two-tailed. An overall comparison of the two groups was made, and we also compared outcomes in subgroups defined according to specific variables: nodal status (N1 or N2), histologic findings (squamous-cell carcinoma or other types), extent of weight loss in the six months before enrollment (<5 percent of body weight or ≥5 percent of body weight), type of lymph-node dissection (complete dissection or systematic sampling), age (<60 years or ≥60 years), sex, race (white or other), ECOG performance status (0, denoting fully active, or 1, denoting ambulatory), and TNM stage (stage II or IIIa).
Multivariate analyses with the Cox proportional-hazards model were used to estimate the simultaneous effects of prognostic factors on survival.13 Stepwise selection was used to ensure more parsimonious models. Variables were retained in the model if the associated two-tailed P values were 0.10 or less. Factors considered for inclusion in the model were the stratification factors (nodal status, histologic findings, extent of weight loss, and type of lymph-node dissection) and selected base-line characteristics (age, sex, race, ECOG performance status, and TNM stage).
Results
Characteristics of the Patients
We enrolled 488 patients from 121 institutions; 242 were randomly assigned to receive radiotherapy alone and 246 to receive radiotherapy and chemotherapy. Table 1Table 1
Characteristics of the Patients. lists the base-line characteristics of the patients. There were no significant differences in stratification factors between the two groups. The operative procedures were performed by 267 surgeons, 192 of whom operated on only one patient. Thirteen surgeons (5 percent) operated on six or more patients (25 percent of the patients). Sixty-five percent of patients underwent lobectomy, and 32 percent underwent pneumonectomy. There was no significant difference between the two groups in the proportions of patients who underwent each type of surgery (P=0.57).Fourteen patients who were assigned to receive chemotherapy and radiotherapy and 11 patients who were assigned to receive radiotherapy alone did not start the treatment (15 declined the treatment, 6 were found to be ineligible, 1 died, and other illnesses developed in 3). Sixty-nine percent of the 232 patients who began chemotherapy and radiotherapy received all or part of the four cycles of chemotherapy, 5 percent received three cycles, and 13 percent received two cycles of chemotherapy. The most common reasons for not completing the planned chemotherapy were the patient's refusal (in the case of 36), excessive toxicity (in the case of 18), and progressive disease (in the case of 8). Eighty-four percent of the 463 patients completed the required radiotherapy (86 percent in the group given radiotherapy alone and 82 percent in the group given chemotherapy and radiotherapy).
Table 2Table 2
Treatment-Related Adverse Effects. lists commonly encountered adverse effects. Side effects of treatment were more common and more severe in the group given chemotherapy and radiotherapy. Sepsis caused two of the four deaths in this group; the other two patients died of pneumonitis and esophagitis, respectively. Two of the three deaths in the radiotherapy group were due to radiation-induced pneumonitis. The third was due to esophagitis.Survival
The median duration of follow-up for all 488 patients was 44 months (range, 15 to 89). The median survival was 39 months (95 percent confidence interval, 30 to 52) in the group assigned to receive radiotherapy alone and 38 months (95 percent confidence interval, 31 to 42) in the group assigned to receive chemotherapy and radiotherapy (Figure 1Figure 1
Kaplan–Meier Estimates of Overall Survival among Patients with Stage II or IIIa Non–Small-Cell Lung Cancer, According to Whether They Received Postoperative Radiotherapy Alone or Radiotherapy and Chemotherapy.). The difference in survival was not significant (P=0.56 by the log-rank test). The relative likelihood of survival in the group assigned to chemotherapy and radiotherapy as compared with the group assigned to radiotherapy alone was 0.93 (95 percent confidence interval, 0.74 to 1.18).When the two groups were compared in subgroups defined according to the four stratification factors, there was no significant difference in survival. There was also no significant difference in survival between the two groups when they were analyzed according to age (<60 years vs. ≥60 years), sex, race, TNM stage (II vs. IIIa), ECOG performance status (0 vs. 1), and the number of operations performed per surgeon (1 vs. ≥2). The factors that significantly influenced survival in the multivariate analysis are presented in Table 3Table 3
Multivariate Analysis of Overall Survival and Time to Recurrence..Recurrence
Data concerning recurrence were available for 470 patients. Recurrence was documented in 53 percent of the patients in the group assigned to receive radiotherapy alone and 56 percent of the patients in the group assigned to receive chemotherapy and radiotherapy (P=0.58). Patterns of recurrence did not differ significantly between the two groups (Table 4Table 4
Patterns of Recurrence.). Relapse within the radiation field was documented in 30 patients (13 percent) in the group given radiotherapy alone and 28 patients (12 percent) in the group given chemotherapy and radiotherapy (P= 0.84). The median time to recurrence was similar in the two groups (P=0.88 by the log-rank test): 30.4 months (95 percent confidence interval, 21.6 to 44.4) in the group given radiotherapy alone and 26.1 months (95 percent confidence interval, 18.4 to 38.5) in the group given chemotherapy and radiotherapy. The relative risk of recurrence in the group assigned to chemotherapy and radiotherapy as compared with the group assigned to radiotherapy alone was 0.98 (95 percent confidence interval, 0.77 to 1.25).Comparison of the two groups with respect to stratification factors revealed no significant difference in the time to recurrence. Results of the multivariate analysis are presented in Table 3.
Ineligible Patients
Of the 488 patients who were enrolled in the study, 103 (21 percent) had insufficient information for a definitive assessment of the pathological stage. Nevertheless, all patients had clear evidence of pathological involvement of either an N1 or an N2 lymph node. Twelve (2 percent) additional patients were deemed ineligible for a variety of nonsurgical reasons. The exclusion of the ineligible patients from the analysis had no effect on any of the major results.
Discussion
This trial was designed with the patients assigned to radiotherapy alone as the control group, because it is widely used and apparently effective in decreasing the risk of local recurrence. The chemotherapy drugs, dosages, and number of cycles that we used were decided on by consensus and reflected what we considered to be a regimen active against non–small-cell lung cancer. Concurrent radiotherapy and chemotherapy was selected to decrease the duration of therapy, avoid a delay in the administration of either type of therapy, and exploit any radiosensitization provided by the chemotherapy.
We were unable to identify any advantage of chemotherapy and radiotherapy over radiotherapy alone in preventing local recurrence or increasing survival. Although the relative likelihood of survival was less than 1 in the group assigned to receive chemotherapy plus radiotherapy, suggesting that radiotherapy alone was superior to chemotherapy and radiotherapy, all the 95 percent confidence intervals included 1. There was therefore no evidence of the superiority of either treatment.
The simultaneous administration of chemotherapy and radiotherapy postoperatively caused a higher incidence of serious side effects than did the postoperative administration of radiotherapy alone. Though a similar percentage of patients in each group were able to complete the full course of radiotherapy, 31 percent of patients were not able to receive all four cycles of chemotherapy. Despite the lack of a difference in treatment-related mortality between the two groups, the morbidity associated with combination therapy must be considered in the design of future trials.
The median survival of patients with stage II or IIIa non–small-cell lung cancer in our trial was longer than in previous reports. It is likely that accurate staging and the general improvement in the care of patients with recurrent cancer are responsible for this result, because no survival advantage has been associated with adjuvant radiotherapy.14
During the eight years between the initiation and the completion of this study, new chemotherapeutic agents with substantial activity against non–small-cell lung cancer were introduced. Some of these newer agents may be administered in the outpatient setting and are associated with fewer and less severe side effects than the combination of cisplatin and etoposide, but they appear to offer no survival advantage.15 Therefore, we believe that the introduction of these new drugs does not change our conclusions.
During the past two decades, the results of nine phase 3 trials of adjuvant therapy involving substantial numbers of patients with resected stage II or IIIa non–small-cell lung cancer have been published. Two studies compared radiotherapy with observation,2,16 two contrasted conventional chemotherapy administered at standard intervals with observation,1,17 and two compared chemotherapy and radiotherapy with radiotherapy alone.3,18 Though a significant increase in disease-free survival was observed in some of these trials, no significant increase in overall survival was documented.
Three other phase 3 trials used a novel approach in which observation was compared with a cisplatin-containing regimen followed by 6 to 12 months of a daily oral chemotherapeutic drug.19-21 All three studies demonstrated a statistically significant improvement in survival among patients who had been assigned to the treatment group. These results are of great interest but require validation before such an approach can be accepted as standard therapy.
The results of a meta-analysis of phase 3 trials of chemotherapy in patients with non–small-cell lung cancer that were conducted between 1965 and 1991 have been reported.22 Eight trials including a total of 1394 patients who were assigned either to receive cisplatin-containing chemotherapy or to undergo observation postoperatively were identified. With treatment, there was an absolute difference in two-year and five-year survival rates of 3 percent and 5 percent, respectively. However, these differences were not significant (P=0.08). Seven other trials compared adjuvant radiotherapy with chemotherapy and radiotherapy; six of them used cisplatin-containing regimens. The absolute increase of 2 percent in two-year and five-year survival among the 807 patients assigned to receive chemotherapy and radiotherapy was not significant (P=0.46). A similar meta-analysis of nine phase 3 studies in which radiotherapy was compared with observation revealed no significant difference in survival between the groups for patients with stage III disease and a possible adverse effect of radiotherapy for patients with stage II disease.14 In the light of these data, we believe that the use of adjuvant chemotherapy should be restricted to clinical trials.
Supported in part by grants from the Public Health Service (CA23318, CA120046, CA31946, CA38926, CA32102, CA16616, CA49957, CA66636, CA21115), the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services.
Source Information
From the Department of Surgery, Beth Israel Medical Center, New York (S.M.K.); the Department of Biostatistics, Dana–Farber Cancer Institute, Boston (S.A.); the Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, Fla. (H.W.); the Department of Radiation Oncology, Oakwood Hospital, Detroit (A.H.); the Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston (R.K.); the Division of Medical Oncology, Ochsner Clinic, Baton Rouge, La. (B.J.B.); the Division of Hematology and Medical Oncology, University of Missouri, Ellis Fischer Cancer Center, Columbia (M.C.P.); the Division of Medical Oncology, University of Washington, Seattle (R.B.L.); and the Division of Medical Oncology, Vanderbilt University, Nashville (D.H.J.). This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., chair); participating cooperative groups included the Cancer and Leukemia Group B, the North Central Cancer Treatment Group, the Radiation Therapy Oncology Group, and the Southwest Oncology Group. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Address reprint requests to Dr. Keller at the Department of Surgery, Beth Israel Medical Center, First Ave. and 16th St., New York, NY 10003, or at skeller@bethisraelny.org.
- References
References
1
Holmes EC ,Gail M . Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986;4:710-715
Web of Science | Medline2
The Lung Cancer Study Group
Full Text | Web of Science | Medline3
The Lung Cancer Study Group
Web of Science | Medline4
Gandara DR ,Wold H ,Perez EA , et al. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 1989;81:790-794
CrossRef | Web of Science | Medline5
Ruckdeschel JC ,Finkelstein DM ,Ettinger DS , et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986;4:14-22
Web of Science | Medline6
Dhingra HM ,Valdivieso M ,Carr DT , et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1985;3:176-183
Web of Science | Medline7
Mountain CF . A new international staging system for lung cancer. Chest 1986;89:Suppl:225S-233S
Web of Science | Medline8
Tisi GM ,Friedman PJ ,Peters RM , et al. Clinical staging of primary lung cancer. Am Rev Respir Dis 1983;127:659-664
Web of Science | Medline9
Keller SM, Weese JL. Technique of mediastinal lymph node dissection for the staging of non-small cell lung cancer. Chicago: American College of Surgeons, 1988 (videotape). (Video library no. 1576.)
10
Mehta CR ,Patel NR . A network algorithm for performing Fisher's exact test in r×c contingency tables. J Am Stat Assoc 1983;78:427-434
CrossRef | Web of Science11
Kaplan EL ,Meier P . Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science12
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline13
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22014
PORT Meta-analysis Trialists Group
CrossRef | Web of Science | Medline15
Belani CP ,Natale RB ,Lee JS , et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Prog Proc Am Soc Clin Oncol 1998;17:455a-455a abstract.16
Mayer R ,Smolle-Juettner FM ,Szolar D , et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest 1997;112:954-959[Erratum, Chest 1998;113:564.]
CrossRef | Web of Science | Medline17
Ohta M ,Tsuchiya R ,Shimoyama M , et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer: results of a randomized prospective study. J Thorac Cardiovasc Surg 1993;106:703-708
Web of Science | Medline18
Dautzenberg B ,Chastang C ,Arriagada R , et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma: a randomized trial of 267 patients. Cancer 1995;76:779-786
CrossRef | Web of Science | Medline19
Wada H, Hitomi S, Teramatsu T, West Japan Study Group for Lung Cancer Surgery
Web of Science | Medline20
The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan)
CrossRef | Medline21
Guangchuan Xu,
Tiehua R ,Peng L . Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: a randomized study. Chin J Oncol 1998;20:228-23022
Non-small Cell Lung Cancer Collaborative Group
CrossRef | Web of Science
- Citing Articles (147)
Citing Articles
1
Roy H. Decker, Corey J. Langer, Kenneth E. Rosenzweig, Joe Yujiao Chang, Richard M. Gewanter, Mark E. Ginsburg, Feng-Ming Kong, Brian E. Lally, Gregory M. Videtic, Benjamin Movsas. (2011) ACR Appropriateness Criteria® Postoperative Adjuvant Therapy in Non-Small Cell Lung Cancer. American Journal of Clinical Oncology 34:5, 537-544
CrossRef2
Elena Galvani, Godefridus J Peters, Elisa Giovannetti. (2011) Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opinion on Investigational Drugs 20:10, 1343-1356
CrossRef3
David P. Carbone, Enriqueta Felip. (2011) Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. Clinical Lung Cancer 12:5, 261-271
CrossRef4
A.-M. Ruppert, L. Belmont, A. Lavolé, V. Gounant, J. Assouad, J. Cadranel, M. Wislez. (2011) Les stratégies thérapeutiques péri-opératoires. Revue des Maladies Respiratoires Actualités 3:4, 346-352
CrossRef5
Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, Elena Collovà, Jessica Menis, Silvia Novello, Emilio Bria. (2011) Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer 73:1, 78-88
CrossRef6
Mi Young Kim, Hong-Gyun Wu, Hak Jae Kim, Dae-Seog Heo, Young Whan Kim, Dong-Wan Kim, Se-Hoon Lee, Joo Hyun Kim, Young Tae Kim, Chang-Hyun Kang. (2011) Role of Postoperative Radiotherapy for Patients with Pathological Stage III Non-Small-Cell Lung Cancer after Curative Resection. The Journal of the Korean Society for Therapeutic Radiology and Oncology 29:1, 44
CrossRef7
T. Le Chevalier. (2010) Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?. Annals of Oncology 21:Supplement 7, vii196-vii198
CrossRef8
S. Oertel, J. Debus, H. Hof, M. Bischof. (2010) Strahlentherapie des Bronchialkarzinoms. Der Radiologe 50:8, 669-674
CrossRef9
Vieri Scotti, Icro Meattini, Calogero Saieva, Benedetta Agresti, Carla de Luca Cardillo, Paolo Bastiani, Lorenzo Livi, Monica Mangoni, Vanessa Di Cataldo, Livia Marrazzo, Andrea Rampini, Samantha Cipressi, Alessio Bruni, Paolo Santini, Giampaolo Biti. (2010) Post-operative radiotherapy in N2 non-small cell lung cancer: A retrospective analysis of 175 patients. Radiotherapy and Oncology 96:1, 84-88
CrossRef10
Mert Saynak, Daniel S. Higginson, David E. Morris, Lawrence B. Marks. (2010) Current Status of Postoperative Radiation for Non–Small-Cell Lung Cancer. Seminars in Radiation Oncology 20:3, 192-200
CrossRef11
L. Crino, W. Weder, J. van Meerbeeck, E. Felip, . (2010) Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v103-v115
CrossRef12
Tommaso De Pas, Sara Raimondi, Giuseppe Pelosi, Lorenzo Spaggiari, Fillipo De Braud, Giulia Veronesi, Patrick Maisonneuve. (2010) A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer. Acta Oncologica 49:4, 480-484
CrossRef13
(2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. The Lancet 375:9722, 1267-1277
CrossRef14
Femke O.B. Spoelstra, Suresh Senan, Cecile Le Péchoux, Satoshi Ishikura, Francesc Casas, David Ball, Allan Price, Dirk De Ruysscher, John R. van Sörnsen de Koste. (2010) Variations in Target Volume Definition for Postoperative Radiotherapy in Stage III Non–Small-Cell Lung Cancer: Analysis of an International Contouring Study. International Journal of Radiation Oncology*Biology*Physics 76:4, 1106-1113
CrossRef15
Naoko Sanuki-Fujimoto, Minako Sumi, Yoshinori Ito, Atsushi Imai, Yoshikazu Kagami, Ikuo Sekine, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura, Hiroshi Ikeda. (2009) Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses. Radiotherapy and Oncology 91:3, 433-437
CrossRef16
Kevin S. Choe, Joseph K. Salama. (2009) Advances in Radiotherapy for Tumors Involving the Mediastinum. Thoracic Surgery Clinics 19:1, 133-141
CrossRef17
Hidefumi Sasaki, Katsuhiro Okuda, Shigeki Shimizu, Minoru Takada, Masaaki Kawahara, Naoto Kitahara, Meinoshin Okumura, Akihide Matsumura, Keiji Iuchi, Tomoya Kawaguchi, Akihito Kubo, Osamu Kawano, Haruhiro Yukiue, Motoki Yano, Yoshitaka Fujii. (2009) EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. Journal of Cancer Research and Clinical Oncology 135:2, 313-318
CrossRef18
Emilio Bria, Richard J. Gralla, Harry Raftopoulos, Federica Cuppone, Michele Milella, Isabella Sperduti, Paolo Carlini, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. (2009) Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials. Lung Cancer 63:1, 50-57
CrossRef19
Edgardo S Santos, Aurelio Castrellon, Marcelo Blaya, Luis E Raez. (2008) Controversies in the management of stage IIIA non-small-cell lung cancer. Expert Review of Anticancer Therapy 8:12, 1913-1929
CrossRef20
Yelena Krupitskaya, Billy W. Loo. (2008) Post-Operative Radiation Therapy (PORT) in Completely Resected Non-Small-Cell Lung Cancer. Current Treatment Options in Oncology 9:4-6, 343-356
CrossRef21
Rachel E. Sanborn, Brian E. Lally. (2008) Adjuvant Therapy for Non–Small Cell Lung Cancer with Mediastinal Nodal Involvement. Thoracic Surgery Clinics 18:4, 423-435
CrossRef22
Tallal Younis, Turki Al-Fayea, Kiran Virik, Wojciech Morzycki, Nathalie Saint-Jacques. (2008) Adjuvant Chemotherapy Uptake in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:11, 1272-1278
CrossRef23
Jean-Yves Douillard, Rafael Rosell, Mario De Lena, Marcello Riggi, Patrick Hurteloup, Marc-Andre Mahe. (2008) Impact of Postoperative Radiation Therapy on Survival in Patients With Complete Resection and Stage I, II, or IIIA Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. International Journal of Radiation Oncology*Biology*Physics 72:3, 695-701
CrossRef24
Shawn S. Groth, Bryan A. Whitson, Michael A. Maddaus. (2008) Radiographic Staging of Mediastinal Lymph Nodes in Non–Small Cell Lung Cancer Patients. Thoracic Surgery Clinics 18:4, 349-361
CrossRef25
Marc M Kueng, Daniel C Betticher. (2008) Treatment in resectable, locally advanced NSCLC: which is the best approach?. Expert Review of Respiratory Medicine 2:5, 655-661
CrossRef26
Bruce J. Giantonio, Arlene A. Forastiere, Robert L. Comis. (2008) The Role of the Eastern Cooperative Oncology Group in Establishing Standards of Cancer Care: Over 50 Years of Progress Through Clinical Research. Seminars in Oncology 35:5, 494-506
CrossRef27
V. Westeel, Denis Moro-Sibilot. (2008) Prise en charge oncologique du patient opéré: chimiothérapie adjuvante, surveillance, traitement des rechutes. Oncologie 10:9, 525-528
CrossRef28
Ana Belén Custodio Carretero, José Ángel García Sáenz, José Luis González Larriba, Jana Bobokova, Antonio Calles Blanco, Florentino Hernando Trancho, Beatriz García Paredes, Laura Rodríguez Lajusticia, Eduardo Díaz-Rubio García. (2008) Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. Clinical and Translational Oncology 10:9, 560-571
CrossRef29
Heather Wakelee, Laveena Chhatwani. (2008) Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 20:3, 198-203
CrossRef30
Bryan A. Whitson, Shawn S. Groth, Michael A. Maddaus. (2008) Recommendations for optimal use of imaging studies to clinically stage mediastinal lymph nodes in non-small-cell lung cancer patients. Lung Cancer 61:2, 177-185
CrossRef31
John M. Varlotto, John C. Flickinger, Abram Recht, Margaret C. Nikolov, Malcolm M. DeCamp. (2008) A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer. Cancer 112:7, 1547-1554
CrossRef32
Jue Wang, Yong Fang Kuo, Jean Freeman, Avi B. Markowitz, James S. Goodwin. (2008) Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer 112:2, 382-390
CrossRef33
Valerie W. Rusch. (2007) Adjuvant Therapy in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 84:5, 1793-1794
CrossRef34
B. Milleron, V. Gounant, É. Giroux-Leprieur, A. Lavolé. (2007) La chimiothérapie postopératoire des cancers bronchiques non à petites cellules. Revue des Maladies Respiratoires 24:8, 64-68
CrossRef35
Bryan A. Whitson, Shawn S. Groth, Michael A. Maddaus. (2007) Surgical Assessment and Intraoperative Management of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 84:3, 1059-1065
CrossRef36
Gerold Bepler. (2007) Phase II Pharmacogenomics-Based Adjuvant Therapy Trial in Patients with Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial 0720. Clinical Lung Cancer 8:8, 509-511
CrossRef37
Brian E. Lally, Frank C. Detterbeck, Ann M. Geiger, Charles R. Thomas, Mitchell Machtay, Antonius A. Miller, Lynn D. Wilson, Timothy E. Oaks, W. Jeffrey Petty, Mike E. Robbins, A. William Blackstock. (2007) The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy. Cancer 110:4, 911-917
CrossRef38
Aaron M. Allen, Robert Den, Julia S. Wong, David Zurakowski, Ricardo Soto, Pasi A. Jänne, Lambros Zellos, Raphael Bueno, David J. Sugarbaker, Elizabeth H. Baldini. (2007) Influence of Radiotherapy Technique and Dose on Patterns of Failure for Mesothelioma Patients After Extrapleural Pneumonectomy. International Journal of Radiation Oncology*Biology*Physics 68:5, 1366-1374
CrossRef39
Giovanni Selvaggi, Giorgio Vittorio Scagliotti. (2007) Perspectives in adjuvant chemotherapy in NSCLC. Expert Review of Respiratory Medicine 1:1, 99-110
CrossRef40
David R. Gandara, Heather Wakelee, Royce Calhoun, David Jablons. (2007) Adjuvant Chemotherapy of Stage I Non-small Cell Lung Cancer in North America. Journal of Thoracic Oncology 2:Supplement 3, S125-S127
CrossRef41
Amy E. Gallo, Jessica S. Donington. (2007) The role of surgery in the treatment of stage III non—small-cell lung cancer. Current Oncology Reports 9:4, 247-254
CrossRef42
Emilio Bria, Federica Cuppone, Fabiana Letizia Cecere, Michele Milella, Cecilia Nisticò, Francesco Cognetti, Edmondo Terzoli. (2007) Adjuvant Chemotherapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:Supplement 1, S7-S11
CrossRef43
Michael T. Milano, Yuhchyau Chen. 2007. Advances in Chemoradiation Treatment of Locoregionally Advanced Non–Small Cell Lung Cancer. , 175-206.
CrossRef44
Leora Horn, Alan Sandler. (2007) Lung Cancer Adjuvant Therapy. The Cancer Journal 13:3, 210-216
CrossRef45
Jacek Jassem. (2007) The role of radiotherapy in lung cancer: Where is the evidence?. Radiotherapy and Oncology 83:2, 203-213
CrossRef46
Daniel B. Costa, Sigui Li, Olivier Kocher, Richard H. Feins, Steven M. Keller, Joan H. Schiller, David H. Johnson, Daniel G. Tenen, Balazs Halmos. (2007) Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590. Lung Cancer 56:1, 97-103
CrossRef47
Steven J. Feigenberg, Alexandra L. Hanlon, Corey Langer, Melvyn Goldberg, Nicos Nicolaou, Michael Millenson, Lawrence R. Coia, Rachelle Lanciano, Benjamin Movsas. (2007) A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:4, 287-292
CrossRef48
Farrah Kassam, Frances A. Shepherd, Michael Johnston, Antonio Visbal, Ronald Feld, Gail Darling, Shaf Keshavjee, Andrew Pierre, Thomas Waddell, Natasha B. Leighl. (2007) Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:1, 39-43
CrossRef49
K. A. Cheong, K. Chrystal, P. G. Harper. (2007) Adjuvant chemotherapy in non-small cell lung cancer. International Journal of Clinical Practice 61:1, 143-146
CrossRef50
Jacek Jassem. (2006) Postoperative chemotherapy in non-small cell lung cancer: still more questions than answers. Future Oncology 2:5, 569-571
CrossRef51
Jean-Yves Douillard, Rafael Rosell, Mario De Lena, Francesco Carpagnano, Rodryg Ramlau, Jose Luis Gonzáles-Larriba, Tomasz Grodzki, Jose Rodrigues Pereira, Alain Le Groumellec, Vito Lorusso, Claude Clary, Antonio J Torres, Jabrail Dahabreh, Pierre-Jean Souquet, Julio Astudillo, Pierre Fournel, Angel Artal-Cortes, Jacek Jassem, Leona Koubkova, Patricia His, Marcello Riggi, Patrick Hurteloup. (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. The Lancet Oncology 7:9, 719-727
CrossRef52
Mario Roselli, Sabrina Mariotti, Patrizia Ferroni, Anastasia Laudisi, Davide Mineo, Eugenio Pompeo, Vincenzo Ambrogi, Tommaso C. Mineo. (2006) Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study. International Journal of Cancer 119:4, 955-960
CrossRef53
Aarati Ranganathan, David R. Gandara. (2006) 2006 Highlights From: 42nd Annual Meeting of the American Society of Clinical Oncology Atlanta, GA, June 2006. Clinical Lung Cancer 8:1, 13-17
CrossRef54
Joe Y. Chang, Jennifer Moughan, David W. Johnstone, Ritsuko Komaki, Melvyn Goldberg, Corey J. Langer, Beth M. Beadle, Jean Owen, Benjamin Movsas. (2006) Surgical Patterns of Care in Operable Lung Carcinoma Treated with Radiation. Journal of Thoracic Oncology 1:6, 526-531
CrossRef55
Kenichi Okubo, Masashi Kobayashi, Hiromasa Morikawa, Eiichi Hayatsu. (2006) Easier node dissection after chemoradiotherapy for lung cancer with collagen insertion at mediastinoscopy. The Japanese Journal of Thoracic and Cardiovascular Surgery 54:7, 268-272
CrossRef56
Anil Potti, Apar Kishor Ganti. (2006) Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future. Expert Opinion on Biological Therapy 6:7, 709-716
CrossRef57
Sarita Dubey, Patricia Stephenson, Donna E. Levy, Judith A. Miller, Steven M. Keller, Joan H. Schiller, David H. Johnson, Jill M. Kolesar. (2006) EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:5, 406-412
CrossRef58
Francesco Grossi, Marcello Tiseo. (2006) Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). Critical Reviews in Oncology/Hematology 58:3, 221-230
CrossRef59
Fred R. Hirsch. (2006) EGFR: A Prognostic and/or a Predictive Marker?. Journal of Thoracic Oncology 1:5, 395-397
CrossRef60
Naveed Alam, Gail Darling, William K. Evans, Jean A. Mackay, Frances A. Shepherd. (2006) Adjuvant chemotherapy for completely resected non-small cell lung cancer: A systematic review. Critical Reviews in Oncology/Hematology 58:2, 146-155
CrossRef61
Naveed Alam, Gail Darling, Frances A. Shepherd, Jean A. Mackay, William K. Evans. (2006) Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review. The Annals of Thoracic Surgery 81:5, 1926-1936
CrossRef62
D C Betticher, S-F Hsu Schmitz, M Tötsch, E Hansen, C Joss, C von Briel, R A Schmid, M Pless, J Habicht, A D Roth, A Spiliopoulos, R Stahel, W Weder, R Stupp, F Egli, M Furrer, H Honegger, M Wernli, T Cerny, H-B Ris. (2006) Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British Journal of Cancer 94:8, 1099-1106
CrossRef63
Mark A. Socinski, Thomas E. Stinchcombe, D. Neil Hayes, David E. Morris. (2006) The Emergence of a Unique Population in Non–Small Cell Lung Cancer: Systemic or Loco-Regional Relapse Following Postoperative Adjuvant Platinum-Based Chemotherapy. Seminars in Oncology 33, 32-38
CrossRef64
Thomas A. d’Amato, Rodney J. Landreneau, Robert J. McKenna, Ricardo S. Santos, Ricardo J. Parker. (2006) Prevalence of In Vitro Extreme Chemotherapy Resistance in Resected Nonsmall-Cell Lung Cancer. The Annals of Thoracic Surgery 81:2, 440-447
CrossRef65
Christopher M. Booth, Frances A. Shepherd. (2006) Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:2, 180-187
CrossRef66
Sung Woo Yang, Pyoung Rak Choi, Hong Jun You, Jin Gu Kim, Chul Ho Oak, Tae Won Jang, Maan Hong Jung. (2006) Relation between ERCC1 Expression in Sputum and Survival after Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases 60:2, 151
CrossRef67
Michael Fanucchi, Fadlo R Khuri. (2006) Taxanes in the Treatment of Non-Small Cell Lung Cancer. Treatments in Respiratory Medicine 5:3, 181-191
CrossRef68
Daniel T. Chang, Robert A. Zlotecki, Kenneth R. Olivier. (2005) Re-Examining the Role of Elective Nodal Irradiation. American Journal of Clinical Oncology 28:6, 597-602
CrossRef69
Linda W. Martin, Arlene M. Correa, Wayne Hofstetter, Waun Ki Hong, Ritsuko Komaki, Joe B. Putnam, David C. Rice, W. Roy Smythe, Stephen G. Swisher, Ara A. Vaporciyan, Garrett L. Walsh, Jack A. Roth. (2005) The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution. The Journal of Thoracic and Cardiovascular Surgery 130:6, 1601-1610.e2
CrossRef70
Paul D. Kiernan, Michael J. Sheridan, James Lamberti, Thomas LoRusso, Vivian Hetrick, Betty Vaughan, Paula Graling. (2005) Late Stage (III and IV) Non-small Cell Cancer of the Lung: Results of Surgical Resection at Inova Fairfax Hospital. Southern Medical Journal 98:11, 1088-1094
CrossRef71
Janessa J Laskin. (2005) Adjuvant chemotherapy for non-small cell lung cancer: the new standard of care. Future Oncology 1:5, 619-623
CrossRef72
William R. Burfeind, David H. Harpole. (2005) Surgical Strategies and Outcomes after Induction Therapy for Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 17:3, 186-190
CrossRef73
Thomas A. D’Amico. (2005) Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 17:3, 195-198
CrossRef74
Rosalyn A. Juergens, Julie R. Brahmer. (2005) Adjuvant therapy for resected non-small-cell lung cancer: Past, present, and future. Current Oncology Reports 7:4, 248-254
CrossRef75
T. Berghmans, M. Paesmans, A.P. Meert, C. Mascaux, P. Lothaire, J.J. Lafitte, J.P. Sculier. (2005) Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer 49:1, 13-23
CrossRef76
Pisters, Katherine M.W., . (2005) Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer — The Smoke Clears. New England Journal of Medicine 352:25, 2640-2642
Full Text77
Winton, Timothy, Livingston, Robert, Johnson, David, Rigas, James, Johnston, Michael, Butts, Charles, Cormier, Yvon, Goss, Glenwood, Inculet, Richard, Vallieres, Eric, Fry, Willard, Bethune, Drew, Ayoub, Joseph, Ding, Keyue, Seymour, Lesley, Graham, Barbara, Tsao, Ming-Sound, Gandara, David, Kesler, Kenneth, Demmy, Todd, Shepherd, Frances, . (2005) Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer. New England Journal of Medicine 352:25, 2589-2597
Full Text78
Harubumi Kato, Masahiro Tsuboi, Yasufumi Kato, Norihiko Ikeda, Tetsuya Okunaka, Chikuma Hamada. (2005) Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer. International Journal of Clinical Oncology 10:3, 157-164
CrossRef79
Heather A. Wakelee, Patricia Stephenson, Steven M. Keller, Henry Wagner, Arnold Herskovic, Ritsuko Komaki, Randolph S. Marks, Michael C. Perry, Robert B. Livingston, David H. Johnson. (2005) Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer 48:3, 389-397
CrossRef80
Julien Dômont, Jean-Charles Soria, Thierry Le Chevalier. (2005) Adjuvant Chemotherapy in Early-Stage Non-Small Cell Lung Cancer. Seminars in Oncology 32:3, 279-283
CrossRef81
Harvey I. Pass. (2005) Mediastinal Staging 2005: Pictures, Scopes, and Scalpels. Seminars in Oncology 32:3, 269-278
CrossRef82
Chandra P. Belani. (2005) Adjuvant and neoadjuvant therapy in non-small cell lung cancer. Seminars in Oncology 32, S9-S15
CrossRef83
Corey J. Langer, Jennifer Moughan, Benjamin Movsas, Ritsuko Komaki, David Ettinger, Jean Owen, J. Frank Wilson. (2005) Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?. Lung Cancer 48:1, 93-102
CrossRef84
Henry Wagner. (2005) Postoperative Radiation Therapy for Patients Who Have Resected Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America 19:2, 283-302
CrossRef85
Gary M. Strauss. (2005) Adjuvant Chemotherapy of Lung Cancer: Methodologic Issues and Therapeutic Advances. Hematology/Oncology Clinics of North America 19:2, 263-281
CrossRef86
Naveed Alam, Frances A. Shepherd, Timothy Winton, Barbara Graham, David Johnson, Robert Livingston, James Rigas, Marlo Whitehead, Keyue Ding, Lesley Seymour. (2005) Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. Lung Cancer 47:3, 385-394
CrossRef87
Thierry Le Chevalier, Rodrigo Arriagada, Jean Pierre Pignon, Giorgio V Scagliotti. (2005) Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?. The Lancet Oncology 6:3, 182-184
CrossRef88
Mircea Dediu, Teodor Horvat, Alin Tarlea, Rodica Anghel, Ioan Cordos, Geanina Miron, Polixenia Iorga, Aurelia Alexandru, Claudiu Nistor, Constantin Grozavu, Cornel Savu. (2005) Adjuvant chemotherapy for radically resected non-small cell lung cancer. Lung Cancer 47:1, 93-101
CrossRef89
M. Noguer Mediavilla, A. Fernández Freire, A. Sabino Álvarez. (2005) Cáncer de pulmón no microcítico. Medicine - Programa de Formación Médica Continuada Acreditado 9:24, 1550-1562
CrossRef90
Johan F Vansteenkiste, Rob H Schildermans. (2005) The future of adjuvant chemotherapy for resected non-small cell lung cancer. Expert Review of Anticancer Therapy 5:1, 165-175
CrossRef91
Ronald L. Burkes, Frances A. Shepherd, Martin E. Blackstein, Melvin E. Goldberg, Paul F. Waters, G. Alexander Patterson, Thomas Todd, F. Griffith Pearson, Donald Jones, Samina Farooq, John McGlaughlin, Robert J. Ginsberg. (2005) Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Lung Cancer 47:1, 103-109
CrossRef92
Hussein Abou-Issa, Galal Alshafie. (2004) Celecoxib: a novel treatment for lung cancer. Expert Review of Anticancer Therapy 4:5, 725-734
CrossRef93
Kenichi Okubo, Tatsuo Kato, Akira Hara, Naoki Yoshimi, Keiichi Takeda, Fumihiko Iwao. (2004) Imprint Cytology for Detecting Metastasis of Lung Cancer in Mediastinal Lymph Nodes. The Annals of Thoracic Surgery 78:4, 1190-1193
CrossRef94
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Lynch, Thomas J., Wright, Cameron D., Choi, Noah C., Aquino, Suzanne L., Mark, Eugene J., . (2004) Case 26-2004. New England Journal of Medicine 351:8, 809-817
Full Text95
Tara L. Lin, Julie R. Brahmer. (2004) Adjuvant therapy for resected non-small-cell lung cancer: Recent advances, emerging agents, and lingering questions. Current Oncology Reports 6:4, 251-258
CrossRef96
Hans Hoffmann. (2004) Resected non-small-cell lung cancer stage I/II: indication for adjuvant/ neoad j uvant therapy?. Lung Cancer 45, S91-S97
CrossRef97
Michael Thomas, Petra Hoffknecht, Cornelia Droege, Andreas Baisch, Niels Reinmuth, Michael Kreuter, Tobias Lange, Wolfgang E. Berdel. (2004) Non-small-cell lung cancer: multimodality approach in stage-III resectable disease. Lung Cancer 45, S99-S105
CrossRef98
Hidenori Takahashi, Satoru Ebihara, Tatsuma Okazaki, Satoshi Suzuki, Masanori Asada, Hiroshi Kubo, Hidetada Sasaki. (2004) Clinical significance of heparanase activity in primary resected non-small cell lung cancer. Lung Cancer 45:2, 207-214
CrossRef99
Steven M Keller, Mark G Vangel, Henry Wagner, Joan H Schiller, Arnold Herskovic, Ritsuko Komaki, Randolph S Marks, Michael C Perry, Robert B Livingston, David H Johnson. (2004) Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease. The Journal of Thoracic and Cardiovascular Surgery 128:1, 130-137
CrossRef100
Tracy E. Kim, John R. Murren. (2004) Therapy for Stage IIIA, IIIB and IV Non???Small Cell Lung Cancer. Clinical Pulmonary Medicine 11:3, 161-174
CrossRef101
Toshihiro Osaki, Akira Nagashima, Takashi Yoshimatsu, Yuko Tashima, Kosei Yasumoto. (2004) Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer 43:2, 151-157
CrossRef102
Hirohito Tada, Ryosuke Tsuchiya, Yukito Ichinose, Teruaki Koike, Nobuhiro Nishizawa, Kanji Nagai, Harubumi Kato. (2004) A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 43:2, 167-173
CrossRef103
Rafael Rosell, Miquel Taron, Aurelio Ariza, Agusti Barnadas, Jose Luis Mate, Noemı́ Reguart, Mireia Margelı́, Enriqueta Felip, Pedro Méndez, Rosario Garcı́a-Campelo. (2004) Molecular predictors of response to chemotherapy in lung cancer. Seminars in Oncology 31, 20-27
CrossRef104
The International Adjuvant Lung Cancer Trial Collaborative Group. (2004) Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer. New England Journal of Medicine 350:4, 351-360
Full Text105
Wood, Alastair J.J., , Spira, Alexander, Ettinger, David S., . (2004) Multidisciplinary Management of Lung Cancer. New England Journal of Medicine 350:4, 379-392
Full Text106
Thierry Le Chevalier. (2004) Adjuvant treatment. American Journal of Cancer 3:Supplement 2, 3-5
CrossRef107
Tsuguo Naruke. (2003) Surgery in locally advanced non-small cell lung cancer. Lung Cancer 42, S11-S15
CrossRef108
Steven M Keller. (2003) Adjuvant therapy for locally advanced non-small cell lung cancer. Lung Cancer 42, S29-S34
CrossRef109
Michael R Johnston. (2003) Induction therapy for stage III lung cancer. Lung Cancer 42, S53-S57
CrossRef110
Giorgio Scagliotti, Silvia Novello. (2003) Adjuvant chemotherapy after complete resection for early stage NSCLC. Lung Cancer 42:2, 47-51
CrossRef111
Noriyoshi Sawabata, Steven M. Keller, Akihide Matsumura, Osamu Kawashima, Tatsuhiko Hirono, Yoshihiko Osaka, Hajime Maeda, Shimao Fukai, Masaaki Kawahara. (2003) The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer. Lung Cancer 42:1, 69-77
CrossRef112
Steven M. Keller, Mark G. Vangel, Henry Wagner, Joan Schiller, Arnold Herskovic, Ritsuko Komaki, Robert Gray, Randolph S. Marks, Michael C. Perry, Robert B. Livingston, David H. Johnson. (2003) Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer 42:1, 79-86
CrossRef113
Hong Zhang, Mei Tian, Sijing Li, Jianzhong Liu, Syuji Tanada, Keigo Endo. (2003) Rhenium-188-HEDP Therapy for the Palliation of Pain Due to Osseous Metastases in Lung Cancer Patients. Cancer Biotherapy & Radiopharmaceuticals 18:5, 719-726
CrossRef114
David R. Spigel, F. Anthony Greco. (2003) Chemotherapy in metastatic and locally advanced non-small cell lung cancer. Seminars in Surgical Oncology 21:2, 98-110
CrossRef115
Giorgio V. Scagliotti, Silvia Novello. (2003) Adjuvant therapy in completely resected non-small-cell lung cancer. Current Oncology Reports 5:4, 318-325
CrossRef116
Angelia D. Gibson, Alan B. Sandler. (2003) Cisplatin-Based Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer. Clinical Lung Cancer 5:1, 18-20
CrossRef117
Giorgio V. Scagliotti, Silvia Novello. (2003) The dream is almost over…don't worry, look ahead. Lung Cancer 40:2, 187-190
CrossRef118
Tracey L. Evans, Thomas J. Lynch. (2003) Recent Advances in the Treatment of Stage IIIA Lung Cancer. Clinical Pulmonary Medicine 10:2, 100-110
CrossRef119
Jacek Jassem. (2003) Role of chemotherapy in the multimodality approach of non-small cell lung cancer. Current Problems in Cancer 27:1, 64-68
CrossRef120
Cesare Gridelli. (2002) Chemotherapy of non-small cell lung cancer in the elderly. Lung Cancer 38, 67-70
CrossRef121
Maurizio Tonato. (2002) Consensus conference on medical treatment of non-small cell lung cancer. Lung Cancer 38, 37-42
CrossRef122
Giorgio Scagliotti. (2002) Consensus development conference on the medical treatment of non-small cell lung cancer: treatment of the early stages. Lung Cancer 38, 23-29
CrossRef123
L Rajdev. (2002) Neoadjuvant and adjuvant therapy of non-small cell lung cancer. Surgical Oncology 11:4, 243-253
CrossRef124
G. Marie Swanson, John C. Bailar. (2002) Selection and description of cancer clinical trials participants?Science or happenstance?. Cancer 95:5, 950-959
CrossRef125
S.M Keller, M.G Vangel, S Adak, H Wagner, J.H Schiller, A Herskovic, R Komaki, M.C Perry, R.S Marks, R.B Livingston, D.H Johnson. (2002) The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer 37:3, 303-309
CrossRef126
James A. Bonner. (2002) The Possible Use of Uniform PORT Doses Is Important in the SEER Analysis, but Undetected Selection Bias Remains an Issue. Clinical Lung Cancer 4:1, 45-46
CrossRef127
Richard H Feins. (2002) Multi-modality treatment of non-small cell lung cancer. Surgical Clinics of North America 82:3, 611-620
CrossRef128
Paul Baas. (2002) Inductive and adjuvant treatment strategies for localized nonsmall cell lung cancer in operable and inoperable patients. Current Opinion in Oncology 14:2, 180-184
CrossRef129
Clifton F Mountain. (2002) Staging classification of lung cancer: A Critical Evaluation. Clinics in Chest Medicine 23:1, 103-121
CrossRef130
Lynn T Tanoue, Ronald B Ponn. (2002) Therapy for stage I and stage II non-small cell lung cancer. Clinics in Chest Medicine 23:1, 173-190
CrossRef131
Cesare Gridelli, Paolo Maione, Emiddio Barletta. (2002) Individualized chemotherapy for elderly patients with nonsmall cell lung cancer. Current Opinion in Oncology 14:2, 199-203
CrossRef132
Nico van Zandwijk. (2001) Neoadjuvant strategies for non-small cell lung cancer. Lung Cancer 34, S145-S150
CrossRef133
P.J Souquet, L Geriniere. (2001) The role of chemotherapy in early stage of non-small cell lung cancer. Lung Cancer 34, S155-S158
CrossRef134
Rafael Rosell, Enriqueta Felip, Jose Maestre, Jose Miguel Sanchez, Jose Javier Sanchez, Jose Luis Manzano, Julio Astudillo, Miquel Taron, Mariano Monzo. (2001) The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer 34, 63-74
CrossRef135
Christian Manegold. (2001) Chemotherapy in Stage I/II NSCLC and projects of the EORTC—Lung Cancer Group for Early Stage Lung Cancer. Lung Cancer 34, 53-58
CrossRef136
Tadeusz M Orlowski, Tomasz J Szczesny. (2001) Surgical treatment of stage III non-small cell lung cancer. Lung Cancer 34, S137-S143
CrossRef137
Christian Rübe, T Phu Nguyen, Jochen Fleckenstein, Markus Niewald. (2001) Postoperative radiotherapy in localized non-small cell lung cancer. Lung Cancer 33, S29-S33
CrossRef138
Michael Thomas, Petra Broermann, Cornelia Droege, Christian Lerchenmüller, Wolfgang E. Berdel. (2001) Development of treatment strategies in locally advanced non-small cell lung cancer (take home messages). Lung Cancer 33, S91-S97
CrossRef139
Martin J Edelman. (2001) Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. Expert Review of Anticancer Therapy 1:2, 229-235
CrossRef140
Bach, Peter B., Cramer, Laura D., Schrag, Deborah, Downey, Robert J., Gelfand, Sarah E., Begg, Colin B., . (2001) The Influence of Hospital Volume on Survival after Resection for Lung Cancer. New England Journal of Medicine 345:3, 181-188
Full Text141
Jorge Mora, William Tester. (2001) Innovative treatments for. Expert Opinion on Investigational Drugs 10:6, 1021-1032
CrossRef142
Douglas J Mathisen. (2001) What’s new in general thoracic surgery. Journal of the American College of Surgeons 192:6, 737-749
CrossRef143
(2001) Adjuvant Chemotherapy for Completely Resected Non–Small-Cell Lung Cancer. New England Journal of Medicine 344:9, 689-690
Full Text144
Nevin Murray, Finbarr Sheehan. (2001) Commentary on “Effectiveness of Radiation Therapy on Non–Small-Cell Lung Cancer”. Clinical Lung Cancer 2:3, 193-194
CrossRef145
James A. Bonner. (2001) Commentary on “Effectiveness of Radiation Therapy on Non–Small-Cell Lung Cancer”. Clinical Lung Cancer 2:3, 191-192
CrossRef146
&NA;. (2000) NSCLC: postoperative adjuvant chemotherapy of no benefit?. Inpharma Weekly &NA;:1262, 15
CrossRef147
Carney, Desmond N., , Hansen, Heine H., . (2000) Non–Small-Cell Lung Cancer — Stalemate or Progress?. New England Journal of Medicine 343:17, 1261-1262
Full Text
